Pieris Pharmaceuticals, Inc. is a clinical-stage biotechnology company. The Company produces differentiated drugs that helps patients suffering from cancer, severe asthma, anemia, and other medical conditions. Pieris Pharmaceuticals serves customers worldwide.

425 | Filing under Securities Act Rule 425 of certain prospectuses and communications in connection with business combination transactions

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Pieris Pharmaceuticals (PIRS US)

425 | Filing under Securities Act Rule 425 of certain prospectuses and communications in connection with business combination transactions

Current Report (Form 8-K | Period ending 2024-12-11)

425 | Filing under Securities Act Rule 425 of certain prospectuses and communications in connection with business combination transactions

Current Report (Form 8-K | Period ending 2024-12-02)

Quarterly Report (Form 10-Q | Period ending 2024-09-30)

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)